Conditions Species β 2 -AROther findings References Protein mRNA β 2 -AR stimulation Fenoterol Rat
(FT)n.d. [4 ] (1.4
, 4 weeks)
(ST) Clenbuterol Rat n.d.
(FT)
1 -AR mRNA
(LV)[7 ] (1.0
, 10 days)
(ST)β 2 -AR mRNA
(LV) Clenbuterol Rat n.d.
(FT)GR mRNA
(FT) [8 ] (1.0
, 10 days)
(ST)HuR mRNA
(FT) AUF1 mRNA
(FT) hnRNP A1 mRNA
(FT) Fenoterol Rat
(FT, ST)
(FT, ST)G
content
(FT, ST) [14 ] (1.4
, 2–7 days) AC activity
(FT, ST) Clenbuterol Rat
(FT+ST)n.d. [15 ] (2.0
, 18 days) Clenbuterol Rat
(FT)n.d. β 2 -AR affinity
(FT)[16 ] (4.0
of feed, 10 days) Clenbuterol Rat
(FT+ST)n.d. [17 ] (0.2
, 7 days) Clenbuterol (50 μ M) Mouse (ex vivo) Phosphorylated n.d. cAMP concentration
[41 ] Formoterol (100 μ M)
-AR
(ST), (FT, ST) Salbutamol (500 μ M)
(FT) Endurance training Treadmill (12 weeks) Rat
(FT)n.d. β 2 -AR afflnity
[18 ] AC activty
G
content
Treadmill (18 weeks) Rat
(FT)n.d. AC activity
(FT, ST) [19 ]
(ST) β 2 -AR density
(acute) Catabolic conditions Dexamethasone Rat
(FT, ST)
(FT)GR mRNA
(FT, ST) [20 ] (1.0
, 10 days)
(ST)CREB mRNA
(ST) AUF1 mRNA
(FT) Dexamethasone Rat n.d.
(FT)GR mRNA
(FT, ST) [21 ] (1.0
, 10 days)
(ST)β 1 -AR mRNA
(LV) Dexamethasone Rat
(FT)n.d. β 2 -AR affinity
(FT)[16 ] (0.2
, 10 days) Casted-immobilization Rat
(FT, ST)
(FT)GR mRNA
(ST) [22 ] (10 days)
(ST)GR protein
(ST) Aging Rat
(FT, ST)n.d. [4 ] Injury Rat
(FT)
(FT)G
content
(FT),
(ST) [14 ] (bupivacaine injection)
(ST)
(ST)AC activity
(FT, ST)
FT, fast-twitch muscle; ST, slow-twitch muscle; LV, left ventricle muscle. Up arrow, increase; down arrow, decrease; lateral arrow, no change. n.d., no data.